16,269
Total Claims
$2.5M
Drug Cost
1,948
Beneficiaries
$1,264
Cost/Patient
Peer Comparison vs. 18,720 Cardiology providers
-17%
Cost per patient vs peers
$1,264 vs $1,524 avg
+22%
Brand preference vs peers
16.6% vs 13.7% avg
Brand vs Generic
83% generic
Brand: 2,708 claims · $2.2M
Generic: 13,561 claims · $307K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Apixaban | 1,360 | $1.3M |
| Rivaroxaban | 346 | $321K |
| Evolocumab | 252 | $212K |
| Sacubitril/Valsartan | 164 | $170K |
| Ranolazine | 408 | $41K |
| Alirocumab | 42 | $32K |
| Empagliflozin | 28 | $30K |
| Flecainide Acetate | 471 | $28K |
| Icosapent Ethyl | 36 | $21K |
| Icosapent Ethyl | 41 | $18K |
| Potassium Chloride | 893 | $17K |
| Metoprolol Succinate | 1,009 | $15K |
| Rosuvastatin Calcium | 855 | $15K |
| Nifedipine | 428 | $14K |
| Dapagliflozin Propanediol | 15 | $12K |
Prescribing Profile
61
Unique Drugs
$1.8M
Patient Profile
76
Avg Age
50%
Female
1.59
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About